Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Similar articles for PubMed (Select 22978063)

1.

Tumor necrosis factors blocking agents: analogies and differences.

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F.

Acta Biomed. 2012 Apr;83(1):72-80. Review.

PMID:
22978063
2.

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T.

Inflamm Bowel Dis. 2013 May;19(6):1224-31. doi: 10.1097/MIB.0b013e318280b169.

PMID:
23619715
3.

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M.

Arthritis Rheum. 2008 May;58(5):1248-57. doi: 10.1002/art.23447.

4.

Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T.

Rheumatology (Oxford). 2010 Jul;49(7):1215-28. doi: 10.1093/rheumatology/keq031. Epub 2010 Mar 1. Review.

5.

Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.

Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G.

Expert Opin Ther Targets. 2008 Sep;12(9):1085-96. doi: 10.1517/14728222.12.9.1085 . Review.

PMID:
18694376
6.

Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C.

J Pharmacol Exp Ther. 2002 May;301(2):418-26.

7.

Differences in binding and effector functions between classes of TNF antagonists.

Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T.

Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.

PMID:
19128982
8.
9.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
10.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ.

Gastroenterology. 2003 Jun;124(7):1774-85.

PMID:
12806611
11.
12.

Update upon efficacy and safety of TNF-α inhibitors.

Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F.

Expert Opin Drug Saf. 2012 Jan;11(1):1-5. doi: 10.1517/14740338.2012.630388. Epub 2011 Oct 20.

PMID:
22010813
13.

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Moreland LW.

Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.

PMID:
15157003
14.

TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2009;16(24):3152-67. Review.

PMID:
19689289
15.

TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide.

Pache I, Rogler G, Felley C.

Swiss Med Wkly. 2009 May 16;139(19-20):278-87. doi: smw-12549. Review.

16.

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach.

Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O.

Ann Rheum Dis. 2012 Feb;71(2):225-30. doi: 10.1136/annrheumdis-2011-200228. Epub 2011 Sep 29.

PMID:
21960560
18.

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.

Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M.

Gastroenterology. 2005 Feb;128(2):376-92.

PMID:
15685549
19.

Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.

Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.

Clin Exp Rheumatol. 2008 May-Jun;26(3):401-7.

PMID:
18578960
20.

Biological therapies for inflammatory bowel disease: research drives clinics.

Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A.

Mini Rev Med Chem. 2006 Jul;6(7):771-84. Review.

PMID:
16842127
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk